Our Sponsor 
For over two decades, Wyeth has been a leader in the creation of recombinant products for people with hemophilia, and introduced the first commercially available recombinant factor VIII and factor IX products. Wyeth produces recombinant hemophilia products exclusively, and currently markets ReFacto Antihemophilic Factor (Recombinant) for the treatment of hemophilia A and BeneFIX Coagulation Factor IX (Recombinant) for the treatment of hemophilia B.
Wyeth also offers educational programs and assistance for people with hemophilia and their families. As part of its strong focus on research and community, the company supports many hemophilia research projects, scientific meetings and patient advocacy organizations.
Click here to learn more about Wyeth's Hemophilia Village.